What Are GLP-1 Receptor Agonists? Evidence, Safety, and Access

Quick Takeaways

• GLP-1 receptor agonists are prescription drugs, not casual wellness supplements.
• Semaglutide activates the GLP-1 receptor and is used in products such as Ozempic, Wegovy, and Rybelsus.
• Tirzepatide activates both GIP and GLP-1 receptors and is used in products such as Mounjaro and Zepbound.
• Human evidence is strong: In STEP 1, semaglutide 2.4 mg produced mean weight loss of 14.9% at 68 weeks versus 2.4% with placebo (PubMed).
• Tirzepatide has large Phase 3 weight-loss data: In SURMOUNT-1, tirzepatide 15 mg produced mean weight loss of 20.9% at 72 weeks versus 3.1% with placebo (NEJM).
• Cardiovascular outcomes changed the conversation: In SELECT, semaglutide reduced major adverse cardiovascular events by 20% in adults with overweight or obesity and established cardiovascular disease without diabetes (American College of Cardiology).
• Safety and access require clinician oversight: FDA labels include a boxed warning for thyroid C-cell tumors and contraindications for personal or family history of medullary thyroid carcinoma or MEN2 for both Wegovy and Zepbound (FDA Wegovy label, FDA Zepbound label).

What GLP-1 Receptor Agonists Do

GLP-1 stands for glucagon-like peptide-1. It is an incretin hormone, meaning it is part of the body's normal response to food. After eating, GLP-1 signaling helps increase glucose-dependent insulin secretion, reduce glucagon when glucose is elevated, slow gastric emptying, and communicate satiety signals to the brain.

GLP-1 receptor agonists extend or amplify that signal. The result is not simply "appetite suppression." The class affects multiple systems at once: pancreatic beta-cell signaling, gastric motility, hypothalamic appetite regulation, cardiometabolic risk markers, and body-weight regulation.

That multi-system mechanism is why these medications can be powerful. It is also why they should be treated as medications with a clinical risk-benefit profile, not as a generic peptide trend.

Semaglutide Versus Tirzepatide

Semaglutide is a GLP-1 receptor agonist. It primarily works through GLP-1 receptor activation. In the United States, semaglutide products have distinct FDA-approved uses depending on brand and formulation, including type 2 diabetes and chronic weight management.

Tirzepatide is different. It is a dual GIP/GLP-1 receptor agonist. GIP stands for glucose-dependent insulinotropic polypeptide, another incretin pathway. Tirzepatide's dual mechanism is one reason it produced larger average weight-loss results in SURMOUNT-1 than semaglutide produced in STEP 1, although those were separate trials and not a direct head-to-head comparison.

The practical clinical point is simple: both are evidence-based prescription medications, but they are not interchangeable without clinician review. Choice depends on indication, contraindications, side-effect history, glucose status, insurance or cash-pay access, patient goals, and monitoring.

What the Human Evidence Shows

The STEP 1 trial enrolled 1,961 adults with obesity or overweight with at least one weight-related condition, excluding diabetes. Participants were randomized to once-weekly semaglutide 2.4 mg or placebo, both with lifestyle intervention, for 68 weeks (PubMed).

At week 68, mean body weight changed by -14.9% in the semaglutide group versus -2.4% with placebo. More semaglutide participants achieved clinically meaningful weight-loss thresholds, including 86.4% achieving at least 5% weight loss versus 31.5% with placebo (PubMed).

The SURMOUNT-1 trial enrolled 2,539 adults with obesity or overweight with at least one weight-related complication, excluding diabetes. Participants received once-weekly tirzepatide 5 mg, 10 mg, 15 mg, or placebo for 72 weeks, including dose escalation (NEJM).

At week 72, mean weight change was -15.0% with tirzepatide 5 mg, -19.5% with 10 mg, -20.9% with 15 mg, and -3.1% with placebo. In the 10 mg and 15 mg groups, 50% and 57% of participants achieved at least 20% weight loss versus 3% with placebo (NEJM).

The SELECT trial added a different type of signal. It studied 17,604 adults with overweight or obesity and established cardiovascular disease but without diabetes, and found that once-weekly semaglutide reduced major adverse cardiovascular events, defined as cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke, compared with placebo (American College of Cardiology).

That outcome matters because it moves semaglutide beyond a scale-only conversation. The strongest scientific framing is no longer just "weight loss." It is cardiometabolic risk reduction in defined populations, with defined entry criteria and defined monitoring.

Mechanism Versus Outcomes

Mechanism explains why a medication might work. Outcomes show what happened in a studied population.

For GLP-1s, the mechanisms are biologically coherent: satiety signaling, delayed gastric emptying, glucose-dependent insulin secretion, and appetite regulation. But the reason this class is so important is that the clinical outcomes are not just theoretical.

The key evidence ladder looks like this:

1. FDA-approved indications: Specific branded products have approved indications for type 2 diabetes, chronic weight management, and other label-defined uses.
2. Randomized controlled trials: STEP 1 and SURMOUNT-1 provide high-quality body-weight outcome data.
3. Cardiovascular outcomes: SELECT supports cardiovascular event reduction in a defined non-diabetic population with established cardiovascular disease.
4. Emerging uses: Liver fat, sleep apnea, addiction biology, neuroinflammation, fertility, and other areas are active research topics, but public messaging should not outrun clinical validation.

That distinction keeps the brand compliant and credible. GLP-1 content should not sound like an ad for thinness. It should sound like clinician-led metabolic education.

Safety, Contraindications, and Monitoring

The FDA labels for Wegovy and Zepbound include a boxed warning about thyroid C-cell tumors observed in rodents and state that the human relevance is unknown. Both labels contraindicate use in patients with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 (FDA Wegovy label, FDA Zepbound label).

Common tolerability issues are gastrointestinal. In STEP 1, more semaglutide participants discontinued treatment due to gastrointestinal events than placebo participants, with 4.5% versus 0.8% discontinuing for GI events (PubMed). In SURMOUNT-1, gastrointestinal events were the most common adverse events with tirzepatide and were generally mild to moderate, occurring primarily during dose escalation (NEJM).

Clinician screening typically considers:

• Contraindications: Personal or family history of medullary thyroid carcinoma, MEN2, serious hypersensitivity, pregnancy status, and product-specific label restrictions.
• Clinical cautions: Prior pancreatitis, gallbladder disease, severe gastrointestinal disease, gastroparesis, diabetic retinopathy risk in patients with diabetes, kidney risk during dehydration, and medication interactions.
• Baseline context: Weight history, HbA1c or glucose status, lipids, kidney function, blood pressure, cardiovascular history, eating disorder history, and medication list.
• Follow-up: Titration tolerance, GI symptoms, hydration, bowel changes, glucose trends when relevant, body-composition strategy, protein intake, and resistance training.

The point is not to scare people away from the class. The point is to treat it with the clinical seriousness it deserves.

Compounded GLP-1s and 2026 Regulatory Caveats

The compounding conversation is one of the highest-risk parts of GLP-1 marketing. During shortage periods, many patients encountered compounded semaglutide or tirzepatide because access to branded products was constrained. As supply stabilized, FDA enforcement posture changed.

In an April 2026 update, FDA reminded compounders that compounded drugs must qualify for exemptions under 503A or 503B, and that 503A compounders may not compound regularly or in inordinate amounts drugs that are essentially copies of commercially available drug products (FDA GLP-1 compounding update). FDA also stated that semaglutide and tirzepatide do not currently appear on the 503B bulks list or FDA's drug shortage list (FDA GLP-1 compounding update).

FDA separately announced a proposal to exclude semaglutide, tirzepatide, and liraglutide from the 503B bulks list, stating it did not identify a clinical need for outsourcing facilities to compound those drugs from bulk substances (FDA press announcement).

For YourHealthRx, the safe position is to avoid broad claims that compounded GLP-1s are equivalent, always available, cheaper substitutes, or automatically appropriate. If a compounded product is discussed at all, it should be framed around individualized prescriber-documented clinical need, pharmacy compliance, sourcing, testing, and legal review.

Consult a specialized healthcare attorney before acting on any GLP-1 sourcing, compounding, affiliate, telehealth, pharmacy, or marketing workflow. This area is actively enforced and fast-moving.

How to Talk About GLP-1s Responsibly

The strongest YourHealthRx positioning is not "get skinny fast." It is evidence-graded metabolic medicine.

Responsible GLP-1 content should:

• Lead with clinical context: These are prescription medications for defined clinical indications.
• Use population averages carefully: Trial results are averages, not guaranteed outcomes.
• Explain chronicity: Obesity and metabolic disease often require long-term management, not short-term cycles.
• Mention lifestyle without moralizing: Protein, resistance training, sleep, and adherence support outcomes, but GLP-1 response is not just willpower.
• Separate access from eligibility: Being interested does not mean being a candidate.
• Keep compounding language conservative: Regulatory status and product quality matter.

That combination builds trust. It also positions YourHealthRx as the brand that explains what the evidence actually says, not the brand chasing the loudest trend.

Bottom Line

GLP-1 receptor agonists are not hype compounds, and they are not casual wellness add-ons. Semaglutide and tirzepatide are prescription medications with strong human data, FDA-approved uses, meaningful cardiometabolic implications, and real safety considerations.

The most accurate frame is signal plus safeguards. The signal is clear: large randomized trials show clinically meaningful weight loss, and SELECT shows cardiovascular outcome benefit for semaglutide in a defined high-risk population. The safeguards are equally important: contraindication screening, dose titration, side-effect management, long-term planning, product quality, and regulatory compliance.

For patients, the question is not "Can I get GLP-1s?" The better question is: "Am I an appropriate candidate, under which indication, through which product pathway, with what monitoring plan, and with what long-term strategy?"